<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schuler, Gerhard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Controversial Issues in TAVI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-28</style></pages><abstract><style  face="normal" font="default" size="100%">There are three major accepted indications for transcatheter aortic valve implantation (TAVI), as well as a number of minor conditions in which TAVI may be reasonable. The first is an inoperable patient with severe aortic stenosis (mean gradient &gt;40 mm Hg or jet velocity &gt;4 m/sec) and surgical risk &gt;50%. The benefit of TAVI in these patients was shown in the PARTNER trial [NCT00530894; Leon MB et al. N Engl J Med 2010], which reported a cardiovascular mortality rate after 1 year of 20.5% for TAVI patients versus 44.6% for patients who received standard therapy (p&lt;0.001).</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>